138 related articles for article (PubMed ID: 16162968)
1. Taurolidine--a new drug with anti-tumor and anti-angiogenic effects.
Jacobi CA; Menenakos C; Braumann C
Anticancer Drugs; 2005 Oct; 16(9):917-21. PubMed ID: 16162968
[TBL] [Abstract][Full Text] [Related]
2. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.
Calabresi P; Goulette FA; Darnowski JW
Cancer Res; 2001 Sep; 61(18):6816-21. PubMed ID: 11559556
[TBL] [Abstract][Full Text] [Related]
3. Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus.
Daigeler A; Chromik AM; Geisler A; Bulut D; Hilgert C; Krieg A; Klein-Hitpass L; Lehnhardt M; Uhl W; Mittelkötter U
Int J Oncol; 2008 Jun; 32(6):1205-20. PubMed ID: 18497982
[TBL] [Abstract][Full Text] [Related]
4. Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma.
Karlisch C; Harati K; Chromik AM; Bulut D; Klein-Hitpass L; Goertz O; Hirsch T; Lehnhardt M; Uhl W; Daigeler A
Int J Oncol; 2013 Mar; 42(3):945-56. PubMed ID: 23338823
[TBL] [Abstract][Full Text] [Related]
5. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine.
Rodak R; Kubota H; Ishihara H; Eugster HP; Könü D; Möhler H; Yonekawa Y; Frei K
J Neurosurg; 2005 Jun; 102(6):1055-68. PubMed ID: 16028765
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.
Chromik AM; Daigeler A; Bulut D; Flier A; May C; Harati K; Roschinsky J; Sülberg D; Ritter PR; Mittelkötter U; Hahn SA; Uhl W
J Exp Clin Cancer Res; 2010 Mar; 29(1):21. PubMed ID: 20205945
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells.
Chromik AM; Daigeler A; Hilgert C; Bulut D; Geisler A; Liu V; Otte JM; Uhl W; Mittelkötter U
J Invest Surg; 2007; 20(6):339-48. PubMed ID: 18097875
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms.
Marcinkiewicz J; Kurnyta M; Biedroń R; Bobek M; Kontny E; Maśliński W
Adv Exp Med Biol; 2006; 583():481-92. PubMed ID: 17153635
[TBL] [Abstract][Full Text] [Related]
9. Is Taurolidine a candidate for treatment of rheumatoid arthritis?
Marcinkiewicz J; Głuszko P; Kontny E; Kwaśny-Krochin B; Bobek M; Wierzchowski W; Ciszek M; Maśliński W
Clin Exp Rheumatol; 2007; 25(2):211-8. PubMed ID: 17543144
[TBL] [Abstract][Full Text] [Related]
10. Taurolidine promotes cell apoptosis by enhancing GRIM‑19 expression in liver cancer.
Li F; Qi J; Qin C; Fu Z; Ren W
Oncol Rep; 2018 Dec; 40(6):3743-3751. PubMed ID: 30272302
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.
Abramjuk C; Bueschges M; Schnorr J; Jung K; Staack A; Lein M
Oncol Rep; 2009 Aug; 22(2):409-14. PubMed ID: 19578784
[TBL] [Abstract][Full Text] [Related]
12. High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats.
Braumann C; Stuhldreier B; Bobrich E; Menenakos C; Rogalla S; Jacobi CA
J Surg Res; 2005 Nov; 129(1):129-35. PubMed ID: 15916768
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer.
Darnowski JW; Goulette FA; Cousens LP; Chatterjee D; Calabresi P
Cancer Chemother Pharmacol; 2004 Sep; 54(3):249-58. PubMed ID: 15173956
[TBL] [Abstract][Full Text] [Related]
14. Novel anti-angiogenic compounds for application in tumor therapy - COP9 signalosome-associated kinases as possible targets.
Braumann C; Tangermann J; Jacobi CA; Müller JM; Dubiel W
Mini Rev Med Chem; 2008 May; 8(5):421-8. PubMed ID: 18473931
[TBL] [Abstract][Full Text] [Related]
15. The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism.
Han Z; Ribbizi I; Pantazis P; Wyche J; Darnowski J; Calabresi P
Anticancer Res; 2002; 22(4):1959-64. PubMed ID: 12174870
[TBL] [Abstract][Full Text] [Related]
16. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
Braumann C; Jacobi CA; Rogalla S; Menenakos C; Fuehrer K; Trefzer U; Hofmann M
J Surg Res; 2007 Dec; 143(2):372-8. PubMed ID: 17612567
[TBL] [Abstract][Full Text] [Related]
17. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis.
Braumann C; Henke W; Jacobi CA; Dubiel W
Int J Cancer; 2004 Nov; 112(2):225-30. PubMed ID: 15352034
[TBL] [Abstract][Full Text] [Related]
18. Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats.
Braumann C; Schoenbeck M; Menenakos C; Kilian M; Jacobi CA
Clin Exp Metastasis; 2005; 22(1):77-83. PubMed ID: 16132581
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of taurolidine in cancer therapy.
Neary PM; Hallihan P; Wang JH; Pfirrmann RW; Bouchier-Hayes DJ; Redmond HP
Ann Surg Oncol; 2010 Apr; 17(4):1135-43. PubMed ID: 20039217
[TBL] [Abstract][Full Text] [Related]
20. Taurolidine induces epithelial-mesenchymal transition via up-regulation of the transcription factor Snail in human pancreatic cancer cell lines.
Hotz B; Erben U; Arndt M; Buhr HJ; Hotz HG
Int J Colorectal Dis; 2014 Nov; 29(11):1339-48. PubMed ID: 25179425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
